Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)
Others
Ratios

BioLineRx (BLRX) Share-based Compensation (IS) (2023 - 2025)

Historic Share-based Compensation (IS) for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $101000.0.

  • BioLineRx's Share-based Compensation (IS) fell 6833.86% to $101000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $194000.0, marking a year-over-year decrease of 9125.34%. This contributed to the annual value of $1.1 million for FY2024, which is 5109.87% down from last year.
  • As of Q3 2025, BioLineRx's Share-based Compensation (IS) stood at $101000.0, which was down 6833.86% from $53000.0 recorded in Q2 2025.
  • Over the past 5 years, BioLineRx's Share-based Compensation (IS) peaked at $929000.0 during Q4 2023, and registered a low of -$154000.0 during Q4 2024.
  • In the last 3 years, BioLineRx's Share-based Compensation (IS) had a median value of $435000.0 in 2023 and averaged $345818.2.
  • Within the past 5 years, the most significant YoY rise in BioLineRx's Share-based Compensation (IS) was 2252.87% (2024), while the steepest drop was 11657.7% (2024).
  • Over the past 3 years, BioLineRx's Share-based Compensation (IS) (Quarter) stood at $929000.0 in 2023, then crashed by 116.58% to -$154000.0 in 2024, then skyrocketed by 165.58% to $101000.0 in 2025.
  • Its Share-based Compensation (IS) was $101000.0 in Q3 2025, compared to $53000.0 in Q2 2025 and $194000.0 in Q1 2025.